<DOC>
	<DOCNO>NCT02238210</DOCNO>
	<brief_summary>Study determine safety Atrovent Nasal Spray 0.06 % pediatric patient ( age 2-5 year ) symptoms rhinorrhea associate naturally occur common cold symptom rhinorrhea associate allergy</brief_summary>
	<brief_title>Safety Trial Atrovent® Pediatric Patients With Rhinorrhea Associated With Common Cold Allergy</brief_title>
	<detailed_description />
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Inclusion Criteria patient common cold Male female least 2 old 5 year age screen Have diagnosis common cold define presence acute onset rhinorrhea ( within 48 hour screen visit ) least 1 follow : Presence swell nasal membrane characteristic common cold examination screen Presence fever 102°F ( oral equivalent ) within 48 hour visit ( may take home/away clinic ) time screen Capability parent/legal guardian read understand inform consent , record trial diary information , administer trial drug read understand trial assessment questionnaire Inclusion Criteria patient allergy Male female least 2 old 5 year age Have diagnosis seasonal perennial allergic rhinitis define follow : Positive skin Radioallergosorbent test ( RAST ) test relevant allergen within 12 month screen screen visit . For purpose trial positive skin test define wheal diameter least 3 mm great negative control Positive prior history atopy nasal symptom associate expose allergen Symptoms associate rhinorrhea least 48 hour prior screen visit Capability parent/legal guardian read understand inform consent , record trial diary information , administer trial drug read understand trial assessment questionnaire General Exclusion Criteria common cold allergy Significant cardiovascular , renal , hepatic , endocrine , metabolic , neurologic systemic disease . A significant disease define one , opinion Investigator , either put patient risk participation trial influence result trial patient 's ability participate trial Presence rales rhonchus suggestive low respiratory tract infection An oral ( equivalent ) temperature high 102°F Presence otitis medium Be initiate advance immunotherapy regimen course trial . Patients receive maintenance dose immunotherapy eligible Known intolerance anticholinergic hypersensitivity benzalkonium chloride Excluded medication prior Visit 1 trial include : 1 . 24 hour Overthecounter decongestant nasal/ocular cromolyn 2 . 3 day : Anticholinergics Overthecounter antihistamine sympathomimetic decongestant 3 . 5 day : Fexofenadine Loratadine 4 . 7 day : Cetirizine antihistamine Atarax® doxepin hydrochloride Antidepressants 5 . 14 day : Intranasal steroids 6 . 28 day : Steroids ( oral injectable ) Leukotriene modifier ( e.g . Accolate® , Singulair® ) Other investigational drug Participation trial investigational drug within 30 day screen visit Nasal obstruction great 50 % would prevent deposition trial drug The parent/legal guardian disability live geographical location could impair compliance protocol visit trial center Exclusion criterion patient common cold History perennial allergic rhinitis seasonal allergic rhinitis ( SAR ) allergen season Positive Streptococcus test Exclusion criterion patient allergy Patients active infectious rhinitis ( common cold ) determine history physical Patients upper low respiratory infection screen</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>